Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma
10.3760/cma.j.cn112139-20201130-00827
- VernacularTitle:PD-1和PD-L1抑制剂在中晚期肝细胞癌中的应用及展望
- Author:
Jing MAO
1
;
Qiang YAN
;
Zhenhua SHEN
;
Xu SUN
;
Shusen ZHENG
Author Information
1. 浙江大学医学院附属湖州医院普外科，浙江湖州313000
- Keywords:
Liver neoplasms;
Combined modality therapy;
Programmed death receptor-1 inhibitor;
Programmed death receptor-ligand 1 inhibitor;
Immunotherapy
- From:
Chinese Journal of Surgery
2021;59(10):875-880
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC) is one of the most common malignant tumors of the digestive system in the clinic. In recent years, the proposal and development of immunotherapy have set off a worldwide anticancer upsurge. In particular, programmed death receptor 1(PD-1) and programmed death receptor ligand 1(PD-L1) inhibitor have been used in a wide variety of tumor diseases and achieved good curative effect. However, the application of PD-1 or PD-L1 inhibitors in HCC is mostly still at the stage of clinical trials, and some clinical trials have shown gratifying results in patients with advanced HCC and postoperative recurrence. More studies have shown that PD-1 or PD-L1 inhibitors combined with radiofrequency, chemoradiotherapy, and molecular targeted drugs can bring greater benefits to patients.
